Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Est. Listeners
Based on iTunes & Spotify (publisher stats).
- Per-Episode Audience
Est. listeners per new episode within ~30 days
25,001 - 50,000 - Monthly Reach
Unique listeners across all episodes (30 days)
25,001 - 75,000 - Active Followers
Loyal subscribers who consistently listen
15,001 - 40,000
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 11 epsHosts
Recent guests
Recent episodes
Q1 earnings take off, Lilly strikes deals, Regeneron notches historic approval, FDA raises questions
Apr 29, 2026
22m 14s
The next era of diabetes management
Apr 23, 2026
21m 42s
Trump’s psychedelics push, Lilly’s up to $7B CAR T deal, Replimune’s saga and Denali’s big win
Apr 22, 2026
26m 08s
Funding the Future of European Biotech
Apr 16, 2026
20m 10s
J&J targets $100B revenue, Replimune rebuffed again and a “Revolution” in pancreatic cancer
Apr 15, 2026
17m 53s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 4/29/26 |  Q1 earnings take off, Lilly strikes deals, Regeneron notches historic approval, FDA raises questions✨ | Q1 earningsbiotech deals+4 | — | DupixentLutathera+13 | — | Q1 earningsbiotech+5 | — | 22m 14s | |
| 4/23/26 |  The next era of diabetes management✨ | diabetes managementhealth technology+3 | Dr. Sarah HowellDr. Wendy S. Lane | Arecor Therapeutics | — | diabetesmanagement+5 | — | 21m 42s | |
| 4/22/26 |  Trump’s psychedelics push, Lilly’s up to $7B CAR T deal, Replimune’s saga and Denali’s big win✨ | psychedelic therapiesCAR T deals+5 | Ryan Watts | AvlayahRP1+9 | — | psychedelicsEli Lilly+8 | — | 26m 08s | |
| 4/16/26 |  Funding the Future of European Biotech✨ | European biotechventure ecosystem+3 | Edoardo NegroniNaveed Siddiqi | AurorA-TTNovo Holdings+1 | — | European biotechventure capital+4 | — | 20m 10s | |
| 4/15/26 |  J&J targets $100B revenue, Replimune rebuffed again and a “Revolution” in pancreatic cancer✨ | biopharma earningsmergers and acquisitions+4 | — | Johnson & JohnsonNovo Nordisk+9 | — | Johnson & JohnsonReplimune+8 | — | 17m 53s | |
| 4/14/26 |  Bonus: Q1 2026 Job Market Update✨ | job marketemployment trends+3 | Angela Gabriel | BioSpace | — | job market2026+3 | — | 8m 33s | |
| 4/9/26 |  Automation, Collaboration and the Future of Advanced Therapies✨ | automationcollaboration+5 | Jason JonesAlexander Seyf | Cellular OriginsAutolomous | — | automationcell therapy+5 | — | 17m 15s | |
| 4/8/26 |  Lilly’s Foundayo Nod Launches New Battle With Novo, M&A Mania Continues, Tariffs Hit Pharma✨ | FDA approvalpharmaceutical industry+4 | — | orforglipronEli Lilly+10 | White House | Eli LillyNovo Nordisk+7 | — | 25m 21s | |
| 4/2/26 |  The Radiotherapeutics Moment: How Isotopes are Changing Cancer Treatment✨ | radiotherapeuticscancer treatment+4 | Marc HedrickPhilip Kantoff | Plus TherapeuticsConvergent Therapeutics | — | radiotherapeuticscancer treatment+4 | — | 18m 30s | |
| 4/1/26 |  Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes✨ | biopharmamergers and acquisitions+4 | — | leukemia drugAvlayah+16 | — | biopharmaM&A+3 | — | 23m 27s | |
| 3/26/26 |  Beyond Buzzwords in Longevity Investing✨ | longevity investingage-related conditions+3 | Sergey JakimovArtem Trotsyuk | LongeVC | — | longevityaging+5 | — | 22m 56s |
Showing 11 of 11
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
16 placements across 15 markets.
Chart Positions
16 placements across 15 markets.